Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
498
Recruiting Now
498
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07106632 Phase 3
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dep...
Condition
Early Breast Cancer
Enrollment
3,380 pts
Location
Belgium, France, Greece
Sponsor
UNICANCER
NCT06711887 Phase 3
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without St...
Condition
Lupus Nephritis
Enrollment
348 pts
Location
United States, Brazil, China
Sponsor
Novartis Pharmaceuticals
NCT07116733 Phase 3
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
Condition
Cardiac Surgery
Enrollment
3,560 pts
Location
China
Sponsor
Xijing Hospital
NCT06733038 Phase 3
Recruiting
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of...
Condition
Colorectal Cancer
Enrollment
238 pts
Location
Italy
Sponsor
Gruppo Oncologico del Nord-Ove
NCT06950385 Phase 3
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Condition
Familial Adenomatous Polyposis (FAP)
Enrollment
168 pts
Location
United States, Denmark, Germany
Sponsor
Rapamycin Holdings Inc.
NCT07752784 Phase 3
Recruiting
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Pos...
Condition
Alzheimer's Disease
Enrollment
12 pts
Location
China
Sponsor
JYAMS PET Research & Developme
NCT07444476 Phase 3
Recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety...
Condition
Spinal Muscular Atrophy
Enrollment
90 pts
Location
United States
Sponsor
Biogen
NCT05851508 Phase 3
Recruiting
The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Pla...
Condition
Meniere Disease
Enrollment
148 pts
Location
Netherlands
Sponsor
Leiden University Medical Cent
NCT04663750 Phase 3
Recruiting
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas f...
Condition
Eye Diseases
Enrollment
210 pts
Location
Germany, Ireland, Netherlands
Sponsor
King's College Hospital NHS Tr
NCT06940947 Phase 3
Recruiting
Endoscopic Therapy Or Surgery for Early Colon Cancer
Condition
Colon Cancer
Enrollment
434 pts
Location
Poland
Sponsor
Norwegian Department of Health
NCT05895838 Phase 3
Recruiting
The Danish Out-of-Hospital Cardiac Arrest Study
Condition
Out-Of-Hospital Cardiac Arrest
Enrollment
1,000 pts
Location
Denmark
Sponsor
Christian Hassager
NCT06418776 Phase 3
Recruiting
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
Condition
Refractory Acute Myeloid Leukemia
Enrollment
198 pts
Location
Russia
Sponsor
National Research Center for H
NCT03150693 Phase 3
Recruiting
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With N...
Condition
B Acute Lymphoblastic Leukemia
Enrollment
303 pts
Location
United States, Canada
Sponsor
Alliance for Clinical Trials i
NCT07215585 Phase 3
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Condition
Large B-cell Lymphoma
Enrollment
420 pts
Location
Australia, Belgium, Brazil
Sponsor
AstraZeneca
NCT04656184 Phase 3
Recruiting
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunog...
Condition
Kawasaki Disease
Enrollment
84 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT07705555 Phase 3
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabeti...
Condition
Diabetic Retinopathy
Enrollment
960 pts
Location
United States
Sponsor
Merck Sharp & Dohme LLC
NCT06522737 Phase 3
Recruiting
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Rel...
Condition
Lymphoma
Enrollment
124 pts
Location
Belgium, Czechia, Denmark
Sponsor
SecuraBio
NCT07668856 Phase 3
Recruiting
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que)...
Condition
Refractory Epilepsy in Children
Enrollment
50 pts
Location
Netherlands
Sponsor
UMC Utrecht
NCT05399537 Phase 3
Recruiting
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Condition
Regional Citrate Anticoagulation (RCA)
Enrollment
40 pts
Location
United States
Sponsor
Vantive Health LLC
NCT06255392 Phase 3
Recruiting
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib...
Condition
Fludzoparib" and Anti-angiogenic
Enrollment
200 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital
NCT06282575 Phase 3
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standar...
Condition
Biliary Tract Cancer
Enrollment
286 pts
Location
United States, Argentina, Belgium
Sponsor
Jazz Pharmaceuticals
NCT07010419 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Ad...
Condition
NSCLC
Enrollment
338 pts
Location
China
Sponsor
Allist Pharmaceuticals, Inc.
NCT07015892 Phase 3
Recruiting
Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II...
Condition
Small Cell Lung Carcinoma
Enrollment
300 pts
Location
Spain
Sponsor
Instituto de Investigación Bio
NCT06747507 Phase 3
Recruiting
Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
Condition
HIV-1-infection
Enrollment
392 pts
Location
Kenya, Lesotho, Mozambique
Sponsor
University of Nairobi
NCT07565428 Phase 3
Recruiting
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Neg...
Condition
Negative Symptoms of Schizophrenia
Enrollment
380 pts
Location
United States
Sponsor
Minerva Neurosciences
Page 1 of 20 — 498 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology